Volume 2 - Issue 3 - May/June 2005

Frank J. Criado

CAS developments were portrayed as “The Perfect Vascular Storm” in the second issue of VDM (December 2004). These were the days before VDM had decided to adopt a new format and become a peer-review journal. In that article, I described and opined… | Read More

David Nicholson, MD, Gary M. Ansel, MD, Charles F. Botti, Jr., MD, Mitchell J. Silver, MD

Introduction Hepatic artery dissection is an uncommon clinical event with few reported cases in the literature. Although rare, most reported dissections have occurred in the setting of intra-arterial hepatic artery chemotherapy or as a complication… | Read More

Vasana Cheanvechai, MD and Steve Busuttil, MD

Endovascular aneurysm repair (EVAR) has emerged as a routine and viable alternative in the treatment of abdominal aortic aneurysms (AAA). Its efficacy has been confirmed in many studies, and its role in the treatment of atherosclerotic aneurysms is… | Read More

Richard Heuser, MD

<i>Emergency Stent-graft Repair for Thoracic Aortic Injury</i> by Castelli et al. | Read More

Patrizio Castelli, MD, Roberto Caronno, MD, Gabriele Piffaretti, MD, Matteo Tozzi, MD, Chiara Lomazzi, MD, Domenico Laganà, MD, Gianpaolo Carrafiello, MD, Salvatore Cuffari, MD

Introduction Blunt thoracic aortic injuries (BTAIs) due to a deceleration trauma are highly lethal and remain a therapeutic challenge. BTAIs represent only 10% of all thoracic vascular traumas and usually involve the isthmic portion of the aorta,… | Read More

Gianpaolo Carrafiello, MD, Domenico Laganá, MD, Monica Mangini, MD, Chiara Recaldini, MD, Domenico Lumia, MD, Andrea Giorgianni, MD, Carlo Fugazzola, MD

Introduction Hemodialysis fistulas (AVFs) are an element of fundamental importance in the treatment of patients undergoing dialysis. Their correct functioning is an indispensable condition for the success of the dialysis procedure. Interventional… | Read More

<sup>1</sup>Giuseppe Patti, MD, <sup>2</sup>Vincenzo Pasceri, MD, <sup>1</sup>Germano Di Sciascio, MD

Percutaneous coronary intervention (PCI) with stenting has been shown to enhance platelet aggregation.1 Accordingly, optimization of antiplatelet therapy has a crucial role in patients undergoing percutaneous revascularization and even more “… | Read More

David E. Allie, MD

Patti et al. have further added to the mounting evidence that optimal antiplatelet therapy translates to clinical benefits in PCI by reporting the results of the ARMYDA-2 trial, which was a prospective, randomized trial between a pretreatment (mean… | Read More

Nicholas W. Shammas, MS, MD

Vascular injury leads to platelet activation and aggregation, and subsequent fibrin deposition and thrombosis. Antithrombin therapy alone without optimal platelet inhibition leads to an inferior outcome during percutaneous coronary intervention (PCI… | Read More

Jeffrey P. Carpenter, MD on behalf of the Endologix Investigators*

Introduction Recently approved by the FDA for sale in the United States, and having been employed in Europe since 1999, the Powerlink device (Endologix, Inc.) is a unibody bifurcated endograft for repair of abdominal aortic aneurysms (AAA) (Figure 1… | Read More

Jeffrey P. Schussler, MD and Kenneth B. Johnson, MD

Renal artery aneurysms are a rare phenomenon, occurring in a small percentage (0.09–2.5%) of the population and with a low associated risk of rupture.1–5 Rupture tends to occur with increasing aneurysm size, and is associated with up to 80% risk of… | Read More